Live Breaking News & Updates on Antigen receptor t

Stay informed with the latest breaking news from Antigen receptor t on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Antigen receptor t and stay connected to the pulse of your community

Integrated cell-cum-gene therapy facility unveiled in Bengaluru

Integrated cell-cum-gene therapy facility unveiled in Bengaluru
Kiran Mazumdar
Bengaluru– Immuneel Therapeutics Ltd, co-founded by Biocon chairperson Kiran Mazumdar-Shaw, unveiled its integrated cell-and-gene therapy development and manufacturing facility at Narayana Hrudayalaya Health City on the outskirts of this tech city on Monday.
“The research-led integrated facility has a hi-tech lab, CGMP-complaint manufacturing suites for cell and gene therapies to treat cancer patients from across the country,” said the city-based company in a statement here.
The Current Good Manufacturing Practices (CGMP) are required to conform to the guidelines recommended by agencies that control authorisation and licensing of the manufacture and sale of pharmaceutical products, dietary supplements and medical devices.

India , Bengaluru , Karnataka , Kiran-mazumdar-shaw , Atmanirbhar-bharat , Devi-shetty , Renu-swarup , Immuneel-therapeutics-ltd , Narayana-health , Biocon , Narayana-hrudayalaya-health-city , Biotechnology-department

Integrated cell-cum-gene therapy facility unveiled in B'luru

Integrated cell-cum-gene therapy facility unveiled in B'luru
By
IANS
|
Published on
Mon, Jan 18 2021 23:51 IST
|
0 Views
Kiran Mazumdar Shaw. Image Source: IANS News
Bengaluru, Jan 18 : Immuneel Therapeutics Ltd, co-founded by Biocon chairperson Kiran Mazumdar-Shaw, unveiled its integrated cell-and-gene therapy development and manufacturing facility at Narayana Hrudayalaya Health City on the outskirts of this tech city on Monday.
"The research-led integrated facility has a hi-tech lab, CGMP-complaint manufacturing suites for cell and gene therapies to treat cancer patients from across the country," said the city-based company in a statement here.
The Current Good Manufacturing Practices (CGMP) are required to conform to the guidelines recommended by agencies that control authorisation and licensing of the manufacture and sale of pharmaceutical products, dietary supplements and medical devices.

India , Bengaluru , Karnataka , Kiran-mazumdar-shaw , Atmanirbhar-bharat , Devi-shetty , Renu-swarup , Immuneel-therapeutics-ltd , Narayana-health , Biocon , Narayana-hrudayalaya-health-city , Biotechnology-department

Worldwide Industry for CAR-T Cell Therapy (2021 to 2027) - Players Profiled Include Aleta BioTherapeutics, Anixa Biosciences and BioNTech Among Others

Share this article
Share this article
ResearchAndMarkets.com's offering.
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as "living drugs."
T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells to recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.

Germany , Wugen , Zhejiang , China , Italy , Dublin , Ireland , France , Spain , Nanjing , Jiangsu , Astellas-adaptimmune